High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

Daratumumab is a CD38‐targeted human monoclonal antibody with direct anti‐myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory multiple myeloma (RRMM) patients treated with daratumumab revealed cytotoxic T‐cell expansion and reduction of immune‐suppressive populations, sug...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cytometry A
Auteurs principaux: Adams, Homer C., Stevenaert, Frederik, Krejcik, Jakub, Van der Borght, Koen, Smets, Tina, Bald, Jaime, Abraham, Yann, Ceulemans, Hugo, Chiu, Christopher, Vanhoof, Greet, Usmani, Saad Z., Plesner, Torben, Lonial, Sagar, Nijhof, Inger, Lokhorst, Henk M., Mutis, Tuna, van de Donk, Niels W.C.J., Sasser, Amy Kate, Casneuf, Tineke
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2018
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590645/
https://ncbi.nlm.nih.gov/pubmed/30536810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cyto.a.23693
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires